Tight control of the APP-Mint1 interaction in regulating amyloid production

Shawna M Henry1, Sabrina A Kistler1, Gavin D Lagani1

  • 1Department of Biology, Boston University, Boston, MA, USA.

Brain Research
|July 27, 2023
PubMed

Insights

Targeting the interaction between amyloid precursor protein (APP) and Mint1 adaptor proteins offers a potential Alzheimer's disease (AD) therapy. Modulating this interaction affects APP processing and Aβ generation.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) peptide generation from amyloid precursor protein (APP).
  • The YENPTY motif on APP mediates its endocytosis, a crucial step in Aβ production.
  • Cytosolic adaptor proteins called Mints bind to the YENPTY motif, influencing APP trafficking and processing.

Purpose of the Study:

  • To investigate the role of the APP-Mint1 interaction in Aβ generation.
  • To examine how specific Mint1 mutations affect APP and Mint1 cellular dynamics and interactions.
  • To assess the therapeutic potential of targeting the APP-Mint1 interaction in Alzheimer's disease.

Main Methods:

  • Generation and analysis of two Mint1 mutants: Mint1Y633A (enhanced APP binding) and Mint1Y549A/F610A (reduced APP binding).
  • Investigation of cellular dynamics of APP and Mint1 in primary murine neurons.
  • Assessment of Mint1's interaction with binding partners, including presenilin1.

Main Results:

  • Mint1Y633A enhanced APP binding and APP endocytosis in neurons.
  • Mint1Y549A/F610A reduced APP affinity and amyloid-beta (Aβ) secretion.
  • The impact of Mint1Y549A/F610A on Aβ release was more significant than complete Mint protein knockdown, highlighting the interaction's critical role.

Conclusions:

  • The interaction between APP and Mint1 is critical for Aβ production.
  • Modulating the APP-Mint1 interaction can alter APP processing and Aβ generation.
  • Targeting the APP-Mint1 interaction presents a promising therapeutic strategy for Alzheimer's disease.